These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34914063)

  • 1. In Silico Design of Recombinant Chimera T Cell Peptide Epitope Vaccines for Visceral Leishmaniasis.
    Machado AS; Martins VT; Humbert MV; Christodoulides M; Coelho EAF
    Methods Mol Biol; 2022; 2410():463-480. PubMed ID: 34914063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleoside Hydrolase NH 36: A Vital Enzyme for the
    Palatnik-de-Sousa CB
    Front Immunol; 2019; 10():813. PubMed ID: 31040850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction and analysis of promiscuous T cell-epitopes derived from the vaccine candidate antigens of Leishmania donovani binding to MHC class-II alleles using in silico approach.
    Kashyap M; Jaiswal V; Farooq U
    Infect Genet Evol; 2017 Sep; 53():107-115. PubMed ID: 28549876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of dominant epitope-based vaccines encoding Gp63, Kmp-11 and Amastin against visceral leishmaniasis.
    Zhang J; He J; Liao X; Xiao Y; Liang C; Zhou Q; Chen H; Zheng Z; Qin H; Chen D; Chen Q; Li J; Chen J
    Immunobiology; 2021 May; 226(3):152085. PubMed ID: 33910113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes.
    Khan MAA; Ami JQ; Faisal K; Chowdhury R; Ghosh P; Hossain F; Abd El Wahed A; Mondal D
    Parasit Vectors; 2020 Apr; 13(1):196. PubMed ID: 32295617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with a CD4
    Dias DS; Ribeiro PAF; Martins VT; Lage DP; Costa LE; Chávez-Fumagalli MA; Ramos FF; Santos TTO; Ludolf F; Oliveira JS; Mendes TAO; Silva ES; Galdino AS; Duarte MC; Roatt BM; Menezes-Souza D; Teixeira AL; Coelho EAF
    Transl Res; 2018 Oct; 200():18-34. PubMed ID: 29908151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of immunomodulatory potential of recombinant histidyl-tRNA synthetase (rLdHisRS) protein of Leishmania donovani as a vaccine candidate against visceral leishmaniasis.
    Kushwaha V; Capalash N
    Acta Trop; 2023 May; 241():106867. PubMed ID: 36878386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome based screening of epitope ensemble vaccine candidates against dreadful visceral leishmaniasis using immunoinformatics approach.
    Singh G; Pritam M; Banerjee M; Singh AK; Singh SP
    Microb Pathog; 2019 Nov; 136():103704. PubMed ID: 31479726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoprophylaxis using polypeptide chimera vaccines plus adjuvant system promote Th1 response controlling the spleen parasitism in hamster model of visceral leishmaniasis.
    Gusmão MR; Ostolin TLVDP; Carvalho LM; Costa AFP; Moreira GJL; Cardoso JMO; Aguiar-Soares RDO; Reis AB; de Brito RCF; Roatt BM
    Vaccine; 2022 Sep; 40(37):5494-5503. PubMed ID: 35963820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunogenicity and protective immunity of multi-epitopes DNA prime-protein  boost vaccines encoding Amastin-Kmp-11, Kmp11-Gp63 and Amastin-Gp63 against visceral leishmaniasis.
    Zhang J; He J; Li J; Zhou Q; Chen H; Zheng Z; Chen Q; Chen D; Chen J
    PLoS One; 2020; 15(3):e0230381. PubMed ID: 32176727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
    Osman M; Mistry A; Keding A; Gabe R; Cook E; Forrester S; Wiggins R; Di Marco S; Colloca S; Siani L; Cortese R; Smith DF; Aebischer T; Kaye PM; Lacey CJ
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis.
    Gupta R; Kumar V; Kushawaha PK; Tripathi CP; Joshi S; Sahasrabuddhe AA; Mitra K; Sundar S; Siddiqi MI; Dube A
    PLoS One; 2014; 9(1):e86073. PubMed ID: 24475071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Th1 stimulatory proteins of Leishmania donovani: comparative cellular and protective responses of rTriose phosphate isomerase, rProtein disulfide isomerase and rElongation factor-2 in combination with rHSP70 against visceral leishmaniasis.
    Jaiswal AK; Khare P; Joshi S; Kushawaha PK; Sundar S; Dube A
    PLoS One; 2014; 9(9):e108556. PubMed ID: 25268700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis.
    Costa LE; Goulart LR; Pereira NC; Lima MI; Duarte MC; Martins VT; Lage PS; Menezes-Souza D; Ribeiro TG; Melo MN; Fernandes AP; Soto M; Tavares CA; Chávez-Fumagalli MA; Coelho EA
    PLoS One; 2014; 9(10):e110014. PubMed ID: 25333662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical Assessment of the Immunogenicity of Experimental Leishmania Vaccines.
    Martins VT; Machado AS; Humbert MV; Christodoulides M; Coelho EAF
    Methods Mol Biol; 2022; 2410():481-502. PubMed ID: 34914064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
    Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C
    Front Immunol; 2018; 9():465. PubMed ID: 29599776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis.
    Baharia RK; Tandon R; Sharma T; Suthar MK; Das S; Siddiqi MI; Saxena JK; Sundar S; Dube A
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003557. PubMed ID: 25745863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.
    Kumar A; Samant M
    Parasite Immunol; 2016 May; 38(5):273-81. PubMed ID: 27009772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoinformatics-based multi-epitope containing fused polypeptide vaccine design against visceral leishmaniasis with high immunogenicity and TLR binding.
    Kumar P; Kumar P; Shrivastava A; Dar MA; Lokhande KB; Singh N; Singh A; Velayutham R; Mandal D
    Int J Biol Macromol; 2023 Dec; 253(Pt 8):127567. PubMed ID: 37866569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.